{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:34:13Z","timestamp":1780673653456,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Coptisine (COP) is a natural compound extracted from\n                      <jats:italic>Rhizoma Coptidis<\/jats:italic>\n                      , and it represses the malignant biological behaviors of bladder cancer cells. However, the underlying molecular mechanism has not been fully elucidated. The aim of this study was to clarify the downstream mechanism by which COP treats bladder cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>SwissTargetPrediction, STITCH, SymMap, ETCM, TCMSP, CTD databases were used to collect the related targets of COP. GeneCards, DisGeNET, TTD and OMIM databases were used to obtain the related targets of bladder cancer. A Venn diagram was used to identify the potential targets of COP in bladder cancer treatment. The protein-protein interaction network was constructed using STRING database, and Cytoscape 3.9.0 software was used to screen the hub targets. The binding relationship between COP and the hub targets was verified by molecular docking and molecular dynamics simulation. After the bladder cell lines T24 and BIU-87 were treated with different doses of COP, the regulatory effects of COP on PI3K\/AKT pathway were investigated with western blotting. Additionally, the tumor-suppressive properties of COP on bladder cancer cells were validated with tumorigenesis model and metastasis model in nude mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RAC-alpha serine\/threonine-protein kinase 1 (AKT1), glycogen synthase kinase 3 beta (GSK3B), caspase-3 (CASP3), tumor necrosis factor (TNF) and cyclin D1 (CCND1) were identified as the main hub targets of COP in bladder cancer treatment. PI3K\/AKT pathway was predicted to be a crucial pathway regulated by COP. The binding affinities between COP and AKT1, GSK3B, CASP3, TNF and CCND1 were high. COP treatment markedly repressed the phosphorylation level of ERK1\/2, AKT1, PI3K p85 and mTOR in T24 and BIU-87 cells, and repressed the tumorigenesis and lung\/liver metastasis of T24 cells in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>COP may be a natural inhibitor for AKT1, GSK3B, CASP3, TNF and CCND1. COP represses PI3K\/AKT pathway to suppress the progression of bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41065-025-00600-7","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:54:37Z","timestamp":1763985277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Coptisine regulates PI3K\/AKT pathway to block bladder cancer progression: a study based on network pharmacology, in vitro and in vivo assays"],"prefix":"10.1186","volume":"162","author":[{"given":"Yu","family":"Xiaohui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Jiangqiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"600_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.2147\/CMAR.S346764","volume":"14","author":"ZJ Li","year":"2022","unstructured":"Li ZJ, Wang DY, Liu ZH. Clinical efficacy and quality of life assessment of partial cystectomy and plasmakinetic transurethral resection of tumor in bladder cancer patients. Cancer Manag Res. 2022;14:389\u201398.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"600_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"600_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/jcmm.14767","volume":"24","author":"R Cao","year":"2020","unstructured":"Cao R, Yuan L, Ma B, Wang G, Qiu W, Tian Y. An EMT-related gene signature for the prognosis of human bladder cancer. J Cell Mol Med. 2020;24(1):605\u201317.","journal-title":"J Cell Mol Med"},{"issue":"2","key":"600_CR4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1053\/j.semnuclmed.2020.02.006","volume":"50","author":"C Seidl","year":"2020","unstructured":"Seidl C. Targets for therapy of bladder cancer. Semin Nucl Med. 2020;50(2):162\u201370.","journal-title":"Semin Nucl Med"},{"issue":"1","key":"600_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5256","volume":"10","author":"V Bilim","year":"2022","unstructured":"Bilim V, Hoshi S. Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non-muscle-invasive bladder cancer (NMIBC). Clin Case Rep. 2022;10(1):e05256.","journal-title":"Clin Case Rep"},{"issue":"2","key":"600_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/nu15020378","volume":"15","author":"R Ru","year":"2023","unstructured":"Ru R, Chen G, Liang X, Cao X, Yuan L, Meng M. Sea cucumber derived triterpenoid glycoside Frondoside A: a potential anti-bladder cancer drug. Nutrients. 2023;15(2):378.","journal-title":"Nutrients"},{"key":"600_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68:100938.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"600_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87344-2","volume":"11","author":"N Inoue","year":"2021","unstructured":"Inoue N, Terabayashi T, Takiguchi-Kawashima Y, Fujinami D, Matsuoka S, Kawano M, et al. The benzylisoquinoline alkaloids, Berberine and coptisine, act against camptothecin-resistant topoisomerase I mutants. Sci Rep. 2021;11(1):7718.","journal-title":"Sci Rep"},{"issue":"1","key":"600_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13880209.2019.1577466","volume":"57","author":"J Wang","year":"2019","unstructured":"Wang J, Wang L, Lou GH, Zeng HR, Hu J, Huang QW, et al. Coptidis rhizoma: a comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. Pharm Biol. 2019;57(1):193\u2013225.","journal-title":"Pharm Biol"},{"issue":"12","key":"600_CR10","doi-asserted-by":"publisher","first-page":"7946","DOI":"10.1111\/jcmm.14725","volume":"23","author":"J Wu","year":"2019","unstructured":"Wu J, Luo Y, Deng D, Su S, Li S, Xiang L, et al. Coptisine from Coptis chinensis exerts diverse beneficial properties: a concise review. J Cell Mol Med. 2019;23(12):7946\u201360.","journal-title":"J Cell Mol Med"},{"key":"600_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113941","volume":"156","author":"Y Liu","year":"2022","unstructured":"Liu Y, Gong S, Li K, Wu G, Zheng X, Zheng J, et al. Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K\/Akt signaling pathway. Biomed Pharmacother. 2022;156:113941.","journal-title":"Biomed Pharmacother"},{"issue":"14","key":"600_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28145398","volume":"28","author":"MF He","year":"2023","unstructured":"He MF, Liang JH, Shen YN, Zhang CW, Yang KY, Liu LC, et al. Coptisine inhibits influenza virus replication by upregulating p21. Molecules. 2023;28(14):5398.","journal-title":"Molecules"},{"issue":"1","key":"600_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00210-019-01710-6","volume":"393","author":"J Zhai","year":"2020","unstructured":"Zhai J, Li Z, Zhang H, Ma L, Ma Z, Zhang Y, et al. Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(1):57\u201365.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"18","key":"600_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810330","volume":"23","author":"S Nakonieczna","year":"2022","unstructured":"Nakonieczna S, Grabarska A, Gawel K, Wr\u00f3blewska-\u0141uczka P, Czerwonka A, Stepulak A, et al. Isoquinoline alkaloids from Coptis chinensis franch: focus on Coptisine as a potential therapeutic candidate against gastric cancer cells. Int J Mol Sci. 2022;23(18):10330.","journal-title":"Int J Mol Sci"},{"key":"600_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108688","volume":"697","author":"SY Kim","year":"2021","unstructured":"Kim SY, Hwangbo H, Kim MY, Ji SY, Lee H, Kim GY, et al. Coptisine induces autophagic cell death through down-regulation of PI3K\/Akt\/mTOR signaling pathway and up-regulation of ROS-mediated mitochondrial dysfunction in hepatocellular carcinoma Hep3B cells. Arch Biochem Biophys. 2021;697:108688.","journal-title":"Arch Biochem Biophys"},{"issue":"4","key":"600_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cbdd.14291","volume":"102","author":"J Li","year":"2023","unstructured":"Li J, Liu X. Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression. Chem Biol Drug Des. 2023;102(4):805\u201314.","journal-title":"Chem Biol Drug Des"},{"key":"600_CR17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.2147\/DDDT.S360790","volume":"16","author":"J Gao","year":"2022","unstructured":"Gao J, Yang S, Xie G, Pan J, Zhu F. Integrating network pharmacology and experimental verification to explore the pharmacological mechanisms of Aloin against gastric cancer. Drug Des Devel Ther. 2022;16:1947\u201361.","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"600_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241234006","volume":"52","author":"XL Huang","year":"2024","unstructured":"Huang XL, Sun Y, Wen P, Pan JC, He WY. The potential mechanism of ursolic acid in the treatment of bladder cancer based on network pharmacology and molecular docking. J Int Med Res. 2024;52(3):3000605241234006.","journal-title":"J Int Med Res"},{"key":"600_CR19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.csbj.2019.07.010","volume":"17","author":"H Geng","year":"2019","unstructured":"Geng H, Chen F, Ye J, Jiang F. Applications of molecular dynamics simulation in structure prediction of peptides and proteins. Comput Struct Biotechnol J. 2019;17:1162\u201370.","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"600_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-023-03938-5","volume":"23","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhang M, Wang L, Zhang L, Ma M, Jing M, et al. Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation. BMC Complement Med Ther. 2023;23(1):122.","journal-title":"BMC Complement Med Ther"},{"issue":"7","key":"600_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2174\/1871520623666221026121600","volume":"23","author":"X Long","year":"2023","unstructured":"Long X, Chen L, Yang J, Dong T, Cheng Q, Wang W, et al. Network-based pharmacology and in vitro validation reveal that Galangin induces apoptosis in bladder cancer cells by promoting the P53 signaling pathway. Anticancer Agents Med Chem. 2023;23(7):847\u201357.","journal-title":"Anticancer Agents Med Chem"},{"issue":"22","key":"600_CR22","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1080\/10408398.2019.1708262","volume":"60","author":"OP Mart\u00ednez-Rodr\u00edguez","year":"2020","unstructured":"Mart\u00ednez-Rodr\u00edguez OP, Thompson-Bonilla MDR, Jaramillo-Flores ME. Association between obesity and breast cancer: molecular bases and the effect of flavonoids in signaling pathways. Crit Rev Food Sci Nutr. 2020;60(22):3770\u201392.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"600_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-014-0070-3","volume":"14","author":"XN Chen","year":"2014","unstructured":"Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, et al. MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014;14:70.","journal-title":"Cancer Cell Int"},{"issue":"21","key":"600_CR24","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-10-0275","volume":"16","author":"S Naito","year":"2010","unstructured":"Naito S, Bilim V, Yuuki K, Ugolkov A, Motoyama T, Nagaoka A, et al. Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer. Clin Cancer Res. 2010;16(21):5124\u201332.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"600_CR25","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1021\/acschembio.9b00564","volume":"14","author":"A Solania","year":"2019","unstructured":"Solania A, Gonz\u00e1lez-P\u00e1ez GE, Wolan DW. Selective and rapid cell-permeable inhibitor of human caspase-3. ACS Chem Biol. 2019;14(11):2463\u201370.","journal-title":"ACS Chem Biol"},{"key":"600_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9929093","volume":"2021","author":"K Niu","year":"2021","unstructured":"Niu K, Li Q, Liu Y, Qiao Y, Li B, Wei C, et al. Molecular targets and mechanisms of scutellariae radix-Coptidis rhizoma drug pair for the treatment of ulcerative colitis based on network pharmacology and molecular docking. Evid Based Complement Alternat Med. 2021;2021:9929093.","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"600_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/modpathol.2013.125","volume":"27","author":"R Seiler","year":"2014","unstructured":"Seiler R, Thalmann GN, Rotzer D, Perren A, Fleischmann A. CCND1\/cyclind1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. Mod Pathol. 2014;27(1):87\u201395.","journal-title":"Mod Pathol"},{"issue":"3","key":"600_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031353","volume":"23","author":"A Barzegar Behrooz","year":"2022","unstructured":"Barzegar Behrooz A, Talaie Z, Jusheghani F, \u0141os MJ, Klonisch T, Ghavami S. Wnt and PI3K\/Akt\/mTOR survival pathways as therapeutic targets in glioblastoma. Int J Mol Sci. 2022;23(3):1353.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"600_CR29","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/j.clgc.2017.10.011","volume":"16","author":"ST Liu","year":"2018","unstructured":"Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A. The current status and future role of the phosphoinositide 3 kinase\/AKT signaling pathway in urothelial cancer: an old pathway in the new immunotherapy era. Clin Genitourin Cancer. 2018;16(2):e269-76.","journal-title":"Clin Genitourin Cancer"},{"key":"600_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110553","volume":"102","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou Y, Huang M, Wang Z, Liu D, Liu J, et al. DHCR7 promotes tumorigenesis via activating PI3K\/AKT\/mTOR signalling pathway in bladder cancer. Cell Signal. 2023;102:110553.","journal-title":"Cell Signal"},{"key":"600_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.738364","volume":"9","author":"W Mao","year":"2021","unstructured":"Mao W, Wang K, Sun S, Wu J, Chen M, Geng J, et al. ID2 inhibits bladder cancer progression and metastasis via PI3K\/AKT signaling pathway. Front Cell Dev Biol. 2021;9:738364.","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"600_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13404","volume":"56","author":"Y Su","year":"2023","unstructured":"Su Y, Wang B, Huang J, Huang M, Lin T. YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer. Cell Prolif. 2023;56(7):e13404.","journal-title":"Cell Prolif"},{"key":"600_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9304552","volume":"2022","author":"X Li","year":"2022","unstructured":"Li X, Liu H, Lv C, Du J, Lian F, Zhang S, et al. Gypenoside-induced apoptosis via the PI3K\/AKT\/mTOR signaling pathway in bladder cancer. Biomed Res Int. 2022;2022:9304552.","journal-title":"Biomed Res Int"},{"issue":"2","key":"600_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7150\/jca.31422","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, Lin F, Chen Y, Wang R, Liu J, Jin Y, et al. Cryptotanshinone inhibites bladder cancer cell proliferation and promotes apoptosis via the PTEN\/PI3K\/AKT pathway. J Cancer. 2020;11(2):488\u201399.","journal-title":"J Cancer"},{"key":"600_CR35","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3079823","volume":"2022","author":"B Chi","year":"2022","unstructured":"Chi B, Sun Y, Zhao J, Guo Y. Deoxyschizandrin inhibits the proliferation, migration, and invasion of bladder cancer cells through ALOX5 regulating PI3K-AKT signaling pathway. J Immunol Res. 2022;2022:3079823.","journal-title":"J Immunol Res"},{"issue":"6","key":"600_CR36","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1042\/EBC20170056","volume":"61","author":"CE Johnson","year":"2017","unstructured":"Johnson CE, Tee AR. Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance. Essays Biochem. 2017;61(6):699\u2013710.","journal-title":"Essays Biochem"},{"issue":"1","key":"600_CR37","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1128\/MCB.06159-11","volume":"32","author":"S Alers","year":"2012","unstructured":"Alers S, L\u00f6ffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1\/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol. 2012;32(1):2\u201311. https:\/\/doi.org\/10.1128\/MCB.06159-11.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"600_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00109-023-02411-7","volume":"102","author":"M Shariq","year":"2024","unstructured":"Shariq M, Khan MF, Raj R, Ahsan N, Kumar P. PRKAA2, MTOR, and TFEB in the regulation of lysosomal damage response and autophagy. J Mol Med (Berl). 2024;102(3):287\u2013311.","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"600_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114173","volume":"441","author":"X Liu","year":"2024","unstructured":"Liu X, Guo B, Li Q, Nie J. mTOR in metabolic homeostasis and disease. Exp Cell Res. 2024;441(2):114173.","journal-title":"Exp Cell Res"},{"issue":"2","key":"600_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12253-017-0250-2","volume":"24","author":"S El-Gendi","year":"2018","unstructured":"El-Gendi S, Abu-Sheasha G. Ki-67 and cell cycle regulators p53, p63 and cyclinD1 as prognostic markers for recurrence\/ progression of bladder urothelial carcinoma. Pathol Oncol Res. 2018;24(2):309\u201322.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"600_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-022-01069-3","volume":"8","author":"Q Wang","year":"2022","unstructured":"Wang Q, Wu S, Gu Y, Liang H, He F, Wang X, et al. RASAL2 regulates the cell cycle and cyclin D1 expression through PI3K\/AKT signalling in prostate tumorigenesis. Cell Death Discov. 2022;8(1):275.","journal-title":"Cell Death Discov"},{"issue":"1","key":"600_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0648-4","volume":"36","author":"S Gao","year":"2017","unstructured":"Gao S, Ge A, Xu S, You Z, Ning S, Zhao Y, et al. PSAT1 is regulated by ATF4 and enhances cell proliferation via the GSK3\u03b2\/\u03b2-catenin\/cyclin D1 signaling pathway in ER-negative breast cancer. J Exp Clin Cancer Res. 2017;36(1):179.","journal-title":"J Exp Clin Cancer Res"},{"key":"600_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118126","volume":"257","author":"L Yang","year":"2020","unstructured":"Yang L, Tian X, Chen X, Lin X, Tang C, Gao Y, et al. Upregulation of Rab31 is associated with poor prognosis and promotes colorectal carcinoma proliferation via the mTOR\/p70S6K\/cyclin D1 signalling pathway. Life Sci. 2020;257:118126.","journal-title":"Life Sci"},{"issue":"3","key":"600_CR44","doi-asserted-by":"publisher","first-page":"707","DOI":"10.20892\/j.issn.2095-3941.2020.0056","volume":"17","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Fan Y, Gao Z, Sun X, Zhang H, Wang Z, et al. SHP2 promotes proliferation of breast cancer cells through regulating cyclin D1 stability via the PI3K\/AKT\/GSK3\u03b2 signaling pathway. Cancer Biol Med. 2020;17(3):707\u201325.","journal-title":"Cancer Biol Med"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00600-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00600-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:11:25Z","timestamp":1764180685000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00600-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["600"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00600-7","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The procedures of animal experiments were approved by the Animal Research Ethics Review Committee of Renmin Hospital of Wuhan University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"232"}}